Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Non-cash Items (2018 - 2025)

Revolution Medicines has reported Non-cash Items over the past 8 years, most recently at $208.4 million for Q4 2025.

  • Quarterly results put Non-cash Items at $208.4 million for Q4 2025, down 24.58% from a year ago — trailing twelve months through Dec 2025 was $208.4 million (down 24.58% YoY), and the annual figure for FY2025 was $208.4 million, down 24.58%.
  • Non-cash Items for Q4 2025 was $208.4 million at Revolution Medicines, up from $177.7 million in the prior quarter.
  • Over the last five years, Non-cash Items for RVMD hit a ceiling of $276.3 million in Q4 2024 and a floor of $44.4 million in Q3 2021.
  • Median Non-cash Items over the past 5 years was $84.6 million (2021), compared with a mean of $111.2 million.
  • Biggest five-year swings in Non-cash Items: crashed 49.15% in 2021 and later surged 140.27% in 2024.
  • Revolution Medicines' Non-cash Items stood at $84.0 million in 2021, then grew by 1.46% to $85.2 million in 2022, then skyrocketed by 35.02% to $115.0 million in 2023, then surged by 140.27% to $276.3 million in 2024, then dropped by 24.58% to $208.4 million in 2025.
  • The last three reported values for Non-cash Items were $208.4 million (Q4 2025), $177.7 million (Q3 2025), and $178.5 million (Q2 2025) per Business Quant data.